Annovis Bio (ANVS) Common Equity (2019 - 2026)
Annovis Bio's Common Equity was -$4.25 million in Q2 2026, compared with $18.33 million a year earlier.
Powered by 
Analysis
Annovis Bio (ANVS) Common Equity (2019 - 2026) Analysis & Trends
At the end of FY2025, Common Equity at Annovis Bio came in at $16.85 million, up 81.0% from FY2024.
- Common Equity shows a five-year compound annual growth rate of 17.4% (FY2020 to FY2025).
- In earlier years, Common Equity was $9.31 million in FY2024, -$7.75 million in FY2023, $28.32 million in FY2022 (-36.3%) and $44.49 million in FY2021 (+490.0%).
- The Q2 2026 figure marks the lowest quarterly Common Equity since Q4 2023.
- Compared with a year earlier, Common Equity was higher in three of the last four quarters, with growth averaging 21.6%.
- The best year-over-year quarter for Common Equity over five years was Q1 2022 (growth of 877.5%); the worst was Q1 2026 (a decline of 87.0%).
- Per Business Quant data, ANVS's Common Equity in the three quarters before Q2 2026 was $3.13 million (Q1 2026), $16.85 million (Q4 2025) and $13.16 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Annovis Bio | 58.80 Mn | 58.80 Mn | - | -4.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.25 Mn |
| Mar 31, 2026 | 3.13 Mn |
| Dec 31, 2025 | 16.85 Mn |
| Sep 30, 2025 | 13.16 Mn |
| Jun 30, 2025 | 18.33 Mn |
| Mar 31, 2025 | 24.05 Mn |
| Dec 31, 2024 | 9.31 Mn |
| Sep 30, 2024 | 7.06 Mn |
| Jun 30, 2024 | -1.75 Mn |
| Mar 31, 2024 | -3.35 Mn |
| Dec 31, 2023 | -7.75 Mn |
| Sep 30, 2023 | 6.66 Mn |
| Jun 30, 2023 | 20.74 Mn |
| Mar 31, 2023 | 20.14 Mn |
| Dec 31, 2022 | 28.32 Mn |
| Sep 30, 2022 | 34.59 Mn |
| Jun 30, 2022 | 38.67 Mn |
| Mar 31, 2022 | 42.70 Mn |
| Dec 31, 2021 | 44.49 Mn |
| Sep 30, 2021 | 46.53 Mn |
API Access
Annovis Bio Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=ANVS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "ANVS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=ANVS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();